Pooled CRISPR screening in pancreatic cancer cells implicates co-repressor complexes as a cause of multiple drug resistance via regulation of epithelial-to-mesenchymal transition
Abstract Background Pancreatic ductal adenocarcinoma (PDAC) patients suffer poor outcomes, including a five-year survival of below 10%. Poor outcomes result in part from therapeutic resistance that limits the impact of cytotoxic first-line therapy. Novel therapeutic approaches are needed, but curren...
Main Authors: | Ryne C. Ramaker, Andrew A. Hardigan, Emily R. Gordon, Carter A. Wright, Richard M. Myers, Sara J. Cooper |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2021-05-01
|
Series: | BMC Cancer |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12885-021-08388-1 |
Similar Items
-
Overexpression of Human ABCB1 and ABCG2 Reduces the Susceptibility of Cancer Cells to the Histone Deacetylase 6-Specific Inhibitor Citarinostat
by: Chung-Pu Wu, et al.
Published: (2021-03-01) -
Pooled extracellular receptor-ligand interaction screening using CRISPR activation
by: Zheng-Shan Chong, et al.
Published: (2018-11-01) -
A benchmark of algorithms for the analysis of pooled CRISPR screens
by: Sunil Bodapati, et al.
Published: (2020-03-01) -
Genome-wide CRISPR screen reveals PSMA6 to be an essential gene in pancreatic cancer cells
by: Jesse Bakke, et al.
Published: (2019-03-01) -
CRISPR Cas9 in Pancreatic Cancer Research
by: Hai Yang, et al.
Published: (2019-10-01)